Jun 2026 (Q2 FY26) — Jul 29, 2026
Amarin Q2 FY26 — Dual Commercial Strategy Drives International Growth and Cost Savings
Read the full callAmarin (AMRN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Amarin earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 42.2 | −42.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -28.4 | −6.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$11.53 +1.86% · +$0.21
Performance −41.3% 1Y
1Y: $19.64 on 17 Oct 2025 → $11.53. High $20.25 (20 Oct 2025), low $11.32 (16 Oct 2026).
- Previous close
- $11.32
- 52-week range
- $11.32 – $20.25
- One year
- −43.06%
Overview
- Symbol
- AMRN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Amarin earnings calls (AMRN)
Financials
What the filings say
Net profit, year on year: +46% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 42 | 62 | 42 | 73 | 50 | 49 | 45 | 42 |
| Operating profit | -25 | -53 | -17 | -16 | -11 | -6 | -11 | -12 |
| Operating margin | −59.5% | −84.3% | −39.9% | −22.0% | −22.4% | −12.9% | −25.1% | −28.4% |
| Profit before tax | -22 | -50 | -14 | -13 | -8 | -1 | -9 | -8 |
| Tax rate | −16.7% | 2.6% | −15.2% | −5.1% | 4.7% | −43.5% | −20.5% | 2.8% |
| Net profit | -25 | -49 | -16 | -14 | -8 | -1 | -11 | -8 |
| EPS ($ per share) | -0.06 | — | -0.04 | -0.03 | -0.02 | — | -0.03 | -0.02 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 247 | 269 | 290 | 294 | 299 | 303 | 305 | 310 |
| Reserves | -1,389 | -1,411 | -1,429 | -1,421 | -1,527 | -1,586 | -1,669 | -1,707 |
| Total liabilities | 233 | 274 | 339 | 401 | 291 | 280 | 199 | 211 |
| Fixed assets | 0 | 2 | 2 | 1 | 1 | 0 | 0 | 0 |
| Investments | — | — | 314 | 235 | 92 | 121 | 173 | 168 |
| Total assets | 386 | 882 | 966 | 1,068 | 886 | 832 | 685 | 671 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -95 | -9 | -22 | -67 | -180 | 7 | -31 | 7 |
| Cash from investing | -0 | -2 | -377 | 104 | 175 | -26 | -46 | 9 |
| Cash from financing | 271 | 410 | -59 | -5 | -0 | 0 | -1 | -2 |
| Net cash flow | 176 | 398 | -458 | 32 | -5 | -18 | -78 | 14 |
| Capital expenditure | -0 | -2 | -0 | — | — | — | — | — |
| Free cash flow | -95 | -12 | -22 | — | — | — | — | — |
Insider filings
52 filings between Jan 2, 2026 and Aug 1, 2026.
Open market
decisions to buy or sellNobody bought or sold AMRN on the open market in this window. The filings below are 26 option exercises and 26 tax withholdings.
Compensation
not trading decisions- 26
- Option exercise — converted options into shares
- 26
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 1, 2026 | Fishman Peter L. SVP, CFO | Tax withheld | 155 | $2.2K |
| Aug 1, 2026 | Fishman Peter L. SVP, CFO | Option exercise | 313 | — |
| Jul 1, 2026 | Ketchum Steven B EVP, Chief Scientific Officer | Option exercise | 3,688 | — |
| Jul 1, 2026 | Ketchum Steven B EVP, Chief Scientific Officer | Tax withheld | 1,887 | $30.1K |
| Jul 1, 2026 | Keenan David Paul EVP, Chief Operating Officer | Option exercise | 3,688 | — |
| Jul 1, 2026 | Keenan David Paul EVP, Chief Operating Officer | Tax withheld | 1,926 | $30.7K |
| Jul 1, 2026 | Fishman Peter L. SVP, CFO | Option exercise | 2,447 | — |
| Jul 1, 2026 | Fishman Peter L. SVP, CFO | Tax withheld | 1,206 | $19.2K |
| Jul 1, 2026 | Provoost Jonathan EVP, Chief Legal Officer | Option exercise | 3,688 | — |
| Jul 1, 2026 | Provoost Jonathan EVP, Chief Legal Officer | Tax withheld | 1,264 | $20.1K |
| Jun 26, 2026 | Berg Aaron President and CEO | Option exercise | 6,250 | — |
| Jun 26, 2026 | Berg Aaron President and CEO | Tax withheld | 3,197 | $52.3K |
| Apr 18, 2026 | Bonfiglio Patrice Eadon Director | Option exercise | 838 | — |
| Apr 18, 2026 | Bonfiglio Patrice Eadon Director | Tax withheld | 403 | $6.0K |
| Apr 18, 2026 | Sullivan Diane E. Director | Tax withheld | 403 | $6.0K |
| Apr 18, 2026 | O'Connor Oliver Director | Option exercise | 838 | — |
| Apr 18, 2026 | O'Connor Oliver Director | Tax withheld | 438 | $6.6K |
| Apr 18, 2026 | Sullivan Diane E. Director | Option exercise | 838 | — |
| Apr 18, 2026 | Sterling Louis III Director | Option exercise | 838 | — |
| Apr 18, 2026 | Sterling Louis III Director | Tax withheld | 403 | $6.0K |
| Apr 18, 2026 | Cohen Paul Director | Option exercise | 838 | — |
| Apr 18, 2026 | Cohen Paul Director | Tax withheld | 403 | $6.0K |
| Apr 18, 2026 | Horn Keith Director | Option exercise | 838 | — |
| Apr 18, 2026 | Horn Keith Director | Tax withheld | 403 | $6.0K |
| Apr 18, 2026 | Odysseas Kostas D Director | Option exercise | 838 | — |
| Apr 18, 2026 | Odysseas Kostas D Director | Tax withheld | 403 | $6.0K |
| Apr 1, 2026 | Fishman Peter L. SVP, CFO | Option exercise | 125 | — |
| Apr 1, 2026 | Fishman Peter L. SVP, CFO | Tax withheld | 62 | $897 |
| Jan 31, 2026 | Keenan David Paul EVP, Chief Operating Officer | Option exercise | 2,246 | — |
| Jan 31, 2026 | Keenan David Paul EVP, Chief Operating Officer | Tax withheld | 1,173 | $18.1K |
| Jan 31, 2026 | Keenan David Paul EVP, Chief Operating Officer | Option exercise | 1,933 | — |
| Jan 31, 2026 | Keenan David Paul EVP, Chief Operating Officer | Tax withheld | 1,010 | $15.6K |
| Jan 31, 2026 | Fishman Peter L. SVP, CFO | Option exercise | 563 | — |
| Jan 31, 2026 | Fishman Peter L. SVP, CFO | Tax withheld | 310 | $4.8K |
| Jan 31, 2026 | Fishman Peter L. SVP, CFO | Option exercise | 1,833 | — |
| Jan 31, 2026 | Fishman Peter L. SVP, CFO | Tax withheld | 1,008 | $15.5K |
| Jan 31, 2026 | Berg Aaron President and CEO | Option exercise | 2,246 | — |
| Jan 31, 2026 | Berg Aaron President and CEO | Tax withheld | 1,235 | $19.0K |
| Jan 31, 2026 | Berg Aaron President and CEO | Option exercise | 1,933 | — |
| Jan 31, 2026 | Berg Aaron President and CEO | Tax withheld | 1,063 | $16.4K |
| Jan 31, 2026 | Ketchum Steven B EVP, Chief Scientific Officer | Option exercise | 2,246 | — |
| Jan 31, 2026 | Ketchum Steven B EVP, Chief Scientific Officer | Tax withheld | 1,235 | $19.0K |
| Jan 31, 2026 | Ketchum Steven B EVP, Chief Scientific Officer | Option exercise | 1,933 | — |
| Jan 31, 2026 | Ketchum Steven B EVP, Chief Scientific Officer | Tax withheld | 1,062 | $16.4K |
| Jan 2, 2026 | Keenan David Paul EVP, Chief Operating Officer | Tax withheld | 1,926 | $26.9K |
| Jan 2, 2026 | Ketchum Steven B EVP, Chief Scientific Officer | Option exercise | 3,688 | — |
| Jan 2, 2026 | Ketchum Steven B EVP, Chief Scientific Officer | Tax withheld | 2,041 | $28.5K |
| Jan 2, 2026 | Provoost Jonathan EVP, Chief Legal Officer | Option exercise | 3,688 | — |
| Jan 2, 2026 | Provoost Jonathan EVP, Chief Legal Officer | Tax withheld | 1,488 | $20.8K |
| Jan 2, 2026 | Keenan David Paul EVP, Chief Operating Officer | Option exercise | 3,688 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AMARIN CORP PLCUK
Free account. Everything above stays public.
Write why you follow AMARIN CORP PLCUK and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading